Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch + Lomb Corporation (BLCO) Q1 2025 Earnings Call Transcript
Bausch + Lomb Corporation (NYSE:BLCO ) Q1 2025 Earnings Conference Call April 30, 2025 8:00 AM ET Company Participants George Gadkowski - Vice President, Investor Relations & Business Insights Brent Saunders - Chairman & Chief Executive Officer Sam Eldessouky - Chief Financial Officer Yehia Hashad - Head, R&D Conference Call Participants Patrick Wood - Morgan Stanley Young Li - Jefferies Joanne Wuensch - Citibank Douglas Miehm - RBC Capital Matt Miksic - Barclays Robbie Marcus - JPMorgan Operator Good morning, and welcome to Bausch + Lomb's First Quarter 2025 Earnings Call. All participants will be in listen-only mode.
Bausch + Lomb (BLCO) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bausch + Lomb (BLCO) Reports Q1 Loss, Misses Revenue Estimates
Bausch + Lomb (BLCO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.07 per share a year ago.
BLCO or DHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last?
Bausch + Lomb (BLCO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bausch + Lomb Corporation (BLCO) Q4 2024 Earnings Call Transcript
Bausch + Lomb Corporation (NYSE:BLCO ) Q4 2024 Results Conference Call February 19, 2025 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations Brent Saunders - CEO & Chairman Sam Eldessouky - Executive VP & CFO Yehia Hashad - Head of R&D and Chief Medical Officer Conference Call Participants Patrick Wood - Morgan Stanley Joanne Wuensch - Citibank Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Denis Reznik - Raymond James Operator Greetings. Welcome to the Bausch + Lomb Fourth Quarter 2024 Earnings Call.
Bausch + Lomb (BLCO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bausch & Lomb to shake up contact lenses with deal off the table
Bausch & Lomb said this month it had explored taking the company private with a third-party buyer. No deal was reached as a consortium of private equity firms TPG and Blackstone reportedly backed out.
Bausch + Lomb (BLCO) Surpasses Q4 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.24 per share a year ago.
Unlocking Q4 Potential of Bausch + Lomb (BLCO): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Bausch + Lomb (BLCO), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
